Department of Head and Neck Surgery, Division of Otolaryngology, Saitama Medical University International Medical Center, Hidaka, Japan.
Department of Clinical Cancer Genomics, Saitama Medical University International Medical Center, Hidaka, Japan.
Acta Otolaryngol. 2021 Jun;141(6):640-645. doi: 10.1080/00016489.2021.1897160. Epub 2021 Apr 1.
Human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma shows a higher rate of radiation resistance than HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). Radioresistant HPV-negative OPSCC is associated with unfavourable outcomes, but validated prognostic biomarkers remain lacking.
AIMS/OBJECTIVES: This study investigated biomarkers for radioresistant HPV-negative OPSCC.
The Cancer Genome Atlas included miRNA sequence and mRNA sequence data from 528 HNSCC tumours. Of these, we used gene expression data for HPV-negative head and neck squamous cell carcinoma for which data were available on the effects of radiation, and compared miRNA sequence and mRNA sequence data between radioresistant and radiosensitive groups. We subsequently estimated downstream miRNA from the results. Finally, we validated miRNAs related to the outcomes of radiotherapy in our clinical cases.
Investigation of miRNA sequence revealed expression of miR-130b as the greatest difference between radiosensitive and radioresistant groups. We subsequently evaluated miR-130b expression in our clinical OPSCC cases. Values of miR-130b >5.372 (low expression), determined from receiver operating characteristic curve analyses, were associated with significantly longer progression-free survival and overall survival ( = .006, = .04, respectively).
Our results suggest that miR-130b has potential as a biomarker for the radiosensitivity of HPV-negative OPSCC.
人乳头瘤病毒（HPV）阴性口咽鳞状细胞癌比 HPV 阳性口咽鳞状细胞癌（OPSCC）表现出更高的放射抵抗率。HPV 阴性 OPSCC 的放射抵抗与不良预后相关，但仍缺乏经证实的预后生物标志物。
目的/目标：本研究旨在探讨 HPV 阴性 OPSCC 的放射抵抗生物标志物。
癌症基因组图谱（The Cancer Genome Atlas）纳入了 528 例头颈部鳞癌的 miRNA 序列和 mRNA 序列数据。其中，我们使用 HPV 阴性头颈部鳞状细胞癌的基因表达数据，这些数据可用于研究辐射的影响，并比较放射抵抗组和放射敏感组的 miRNA 序列和 mRNA 序列数据。随后，我们根据结果估计下游 miRNA。最后，我们验证了与我们临床病例放射治疗结果相关的 miRNA。
miRNA 序列分析显示，miR-130b 的表达在放射敏感组和放射抵抗组之间差异最大。我们随后评估了我们的临床 OPSCC 病例中的 miR-130b 表达。来自受试者工作特征曲线分析的 miR-130b 值>5.372（低表达）与无进展生存和总生存显著延长相关（ = .006， = .04，分别）。
我们的研究结果表明，miR-130b 有可能成为 HPV 阴性 OPSCC 放射敏感性的生物标志物。
